Progress, Potential, and Possibilities Podcast / Show

Send us Fan MailWilliam Ho is a Co-Founder, and has served as the President, Chief Executive Officer, and Director of IN8bio ( https://in8bio.com/ ), a biotech company with a mission of developing next-generation therapies for treating cancer, with a focus on gamma-delta T cells, since its inception.  Mr. Ho has worked in the biotechnology industry for nearly 24 years. Prior to the founding of IN8bio, from 2014 to 2017, Mr. Ho was the Founder and Managing Partner at AlephPoint Capital, a private healthcare investment fund. Prior to that, Mr. Ho was at New Leaf Venture Partners, a leading healthcare venture capital firm, where he launched and managed the public investments and cross-over portfolio and served as its Public Investment Director from 2010 to 2014. Previously, Mr. Ho served as a Senior Equity Research Analyst at Bank of America from 2006 to 2009 and an Equity Research Analyst at Piper Jaffray & Co. from 2003 to 2006, covering the biotechnology and life-science tools sectors. Earlier in his career, Mr. Ho was responsible for FP&A and operational analysis at CuraGen Corporation and worked as an Associate on the Healthcare Investment Banking team at Cowen, Inc. Mr. Ho was an inductee into the McMaster University Alumni Gallery in 2020 and previously served as a member of their Dean’s Advisory Board for the Faculty of Science. Mr. Ho received an MBA from the University of Notre Dame and a B.S. in Biochemistry from McMaster University.#WilliamHo #IN8bio #GammaDeltaTCells #ImmuneSystem #Glioblastoma #AcuteMyeloidLeukemia #NonSignalingCART #InducedPluripotentStemCells#Oncology #Immunooncology #Cancer #ProgressPotentialAndPossibilities #IraPastor #Podcast #Podcaster #ViralPodcast #STEM #Innovation #Technology #Science #ResearchSupport the show

Send us Fan MailDr. Thomas Ehmer, Ph.D.  ( https://www.linkedin.com/in/tehmer/ ) is a seasoned technology strategist with over two decades of experience in IT innovation, business development, and R&D within the pharmaceutical industry, and co-founder of the Quantum Interest Group, at Merck KGaA Darmstadt, Germany ( https://www.emdgroup.com/en ). Dr. Ehmer currently is in the Sector Data Office - AI Governance and Innovation Incubator at Merck KGaA Darmstadt, Germany, where he scouts emerging and disruptive technologies, demonstrating their potential value for R&D applications, with a focus on quantum technologies. Throughout his career at Merck KGaA Darmstadt, Germany, Dr. Ehmer has played a pivotal role in shaping IT strategy, business process optimization, and digital transformation across the entire pharmaceutical value chain, currently focusing on transparent AI and how and where emerging technology can help patients live a better life. His expertise spans technology scouting, business analysis, and IT program leadership, having successfully driven major global projects. Beyond his corporate career, Dr. Ehmer is an active private seed investor and has contributed to quantum computing research and applications in drug discovery, authoring publications on the potential of quantum computing and machine learning in pharmaceutical R&D ( https://onlinelibrary.wiley.com/doi/10.1002/9783527840748.ch26 ). Dr. Ehmer holds a Ph.D. in Physics, Biophysics, and Physiology from Heidelberg University and continues to mentor within the German Physical Society / Deutsche Physikalische Gesellschaft (DPG). His forward-thinking approach, combined with deep technical expertise, has earned him multiple innovation awards, and he remains dedicated to bridging the gap between emerging technologies and real-world industry applications.Important Episode Link - Entangled Health Podcast - https://podcasts.apple.com/us/podcast/entangled-health/id1819364423#ThomasEhmer #MerckKGaADarmstadt #Physics #Biophysics #Physiology #GermanPhysicalSociety #QuantumComputing #QuantumSensing #MolecularImaging #Spectroscopy #DrugScreening #Diagnostics #QuantumSensors #QuantumMagnetometers #QuantumGravimeters #Biomanufacturing #QualityControl #Neuroscience #BrainDrugInterface #ReservoirComputing #QuantumMachineLearning #Bioconvergence  #ProgressPotentialAndPossibilities #IraPastor #Podcast #Podcaster #ViralPodcast #STEM #Innovation #Technology #Science #ResearchSupport the show

Send us Fan MailJosh Haimson is Co-Founder and CEO of Inductive Bio ( https://www.inductive.bio/about ), a technology company focused on democratizing artificial intelligence (AI) models to transform small molecule drug discovery, eliminating Absorption, Distribution, Metabolism, Excretion and Toxicology (ADMET) bottlenecks with state-of-the-art AI models and generative chemistry, powered by a unique pre-competitive data consortium.Josh has spent his career focused on the intersection of machine learning, product, and life sciences/healthcare.Prior to Inductive, Josh was the Director of Product for the ML and data curation organizations at Flatiron Health, where his teams worked to generate real-world evidence (RWE) at scale across Flatiron’s network of over 2 million active cancer patients for use by researchers in pharma, academia, and government.Prior to Flatiron, Josh was at MIT studying computer science and working with researchers at Massachusetts General Hospital to use ML and NLP to predict patient response to cardiac resynchronization therapy.#JoshHaimson #InductiveBio #SmallMolecule #DrugDiscovery #Absorption #Distribution #Metabolism #Excretion #Toxicology #ADMET #AI #GenerativeChemistry #MachineLearning #CardiacResynchronizationTherapy #MolecularGlue #FlatironHealth #PreCompetitiveDataConsortium #RealWorldEvidence #RealWorldData #RWE #ArtificialIntelligence  #ProgressPotentialAndPossibilities #IraPastor #Podcast #Podcaster #ViralPodcast #STEM #Innovation #Technology #Science #ResearchSupport the show

Send us Fan MailDr. Shai Melcer, Ph.D. is Head of the National Bioconvergence Program ( https://bioconvergence.org.il/ ) at the Israel Innovation Authority ( https://innovationisrael.org.il/en/ ).In this role, Dr. Melcer, who brings 15 years of experience and entrepreneurship in the bio-medical ecosystem, leads the implementation of the bioconvergence goals for TELEM – the National Infrastructure Forum for Research and Development ( https://innovationisrael.org.il/en/programs/telem-the-national-infrastructure-forum-for-research-and-development/ ). Dr. Melcer has both an LLM in Law and Ph.D. in genetics from the Hebrew University, and has collaborated with various entities such as the Hebrew University, Hadassah Medical Center, IBM, the Jerusalem Development Authority (Bio-Jerusalem), and others to establish numerous innovative bio-med ventures, including BioGiv, BIOHOUSE, and Hadassah Accelerator.In his public and private sector activities, Dr. Melcer has worked with hundreds of biomedical companies in Israel and around the world in the fields of pharma-biotech, medical devices, and digital health, many of which are in the bioconvergence sector. He also served as the Chief Business Officer at Minovia, a company in the liquid biopsy consortium established by the Israel Innovation Authority as part of the bio-convergence program.#Bioconvergence #IsraelInnovationAuthority #ShaiMelcer #BugEra #Biotic #ClimateTech #Biomanufacturing #Biofuel #Biodiesel #SustainableAviationFuel #BlackSoldierFly #BiodegradablePolymers #BioBased #Microplastics #CarbonFootprint #Renewable #Sustainable #TechnologicalIncubators #InnovationCenters #AngelInvestors  #ProgressPotentialAndPossibilities #IraPastor #Podcast #Podcaster #Podcasting #ViralPodcast #STEM #Innovation #Science #Technology #ResearchSupport the show

Send us Fan MailDr. Robert Schwab, MD is a Resident Physician, Research Specialist, and Hematology-Oncology Fellow at Penn Medicine, University of Pennsylvania Health System ( https://www3.pennmedicine.org/departments-and-centers/department-of-medicine/divisions/hematology-and-oncology/education-and-training/hematology-oncology-fellowship/fellows ).Dr. Schwab’s work to date has focused on leukemia and bone marrow transplantation, and previously, he worked as a research specialist in Dr. Carl June's laboratory, investigating cancer immunotherapy and CAR-T cell treatments. More recently Dr. Schwab's research is centered on studying novel CAR-T cell therapy applications for addressing inflammation and atherosclerosis related to malignancies. In 2019, he founded Cartio Therapeutics, a biotech startup dedicated to developing cellular immunotherapy for cardiovascular disease. Dr. Schwab received his Doctor of Medicine (M.D.) and Master of Science - MS, Translational Research, from the University of Pennsylvania and Bachelor of Arts (B.A.), Biophysics and Biochemistry from Amherst.#RobertSchwab #PennMedicine #UniversityOfPennsylvaniaHealthSystem #CART #CarlJune #CancerImmunotherapy #CardiovascularDisease #AtheroscleroticPlaques #Atherosclerosis #Macrophages #OxidizedLDL #FoamCells #CARTregs #ChimericAntigenReceptor #TRegulatoryCells #ClonalHematopoiesisOfIndeterminatePotential #CVD #CheckpointInhibitors #Autoimmune  #Cancer #Oncology #HematologyOncology #ProgressPotentialAndPossibilities #IraPastor #Podcast #Podcaster #Podcasting #ViralPodcast #STEM #Innovation #Science #Technology #ResearchSupport the show

Send us Fan MailDaniel Schmitt is President & Chief Executive Officer of Actuate Therapeutics, Inc. ( https://actuatetherapeutics.com/ ), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers through the inhibition of glycogen synthase kinase-3 beta (GSK-3β).Mr. Schmitt brings over 30 years of successful industry experience in operations management, new product development, and business development, having held senior executive positions in both large pharmaceutical and small biotechnology companies, including Fujisawa, Searle / Pharmacia, and Ilex Oncology. During his career, Daniel has led and contributed to the successful development and launch of multiple pharmaceutical products, and has constructed and executed numerous high value licensing, acquisition, and development deals for biotech and pharmaceutical companies, totaling nearly $1 billion in upfront and potential milestone payments.Mr. Schmitt received his M.B.A and a B.S. in Chemistry from West Virginia University, and has held research positions affiliated with the National Foundation for Cancer Research and at the University of North Carolina School of Medicine. He has served as an Entrepreneur-in-Residence at Northwestern University, and as an external expert consultant for the University of Chicago and the University of Illinois-Chicago. Mr. Schmitt is also a founding member of Chicago Innovation Mentors.#ActuateTherapeutics #GlycogenSynthaseKinase3Beta #GSK3β #Oncology #Cancer #Elraglusib #PancreaticDuctalAdenocarcinoma #PDAC #EwingSarcoma #Melanoma #ProgressionFreeSurvival #ProgressPotentialAndPossibilities #IraPastor #Podcast #Podcaster #ViralPodcast #STEM #Innovation #Technology #Science #ResearchSupport the show

Send us Fan MailDr. Frank Bedu-Addo, Ph.D. has served as a director, president and CEO of PDS Biotech ( https://pdsbiotech.com/ ) since its inception in 2005, a biotech company focused on transforming how the immune system targets and fights disease by developing a new generation of targeted cancer treatments.Dr. Bedu-Addo is a veteran biotech executive with experience successfully starting and growing biotechnology organizations. He has been responsible for the development and implementation of both operational and drug development strategies, supervising and managing both large organizations and emerging biotechnology companies.Dr. Bedu-Addo was a founding and senior executive at KBI BioPharma, Inc. As Vice President of Drug Development, he oversaw all business and drug development operations. Before his tenure at KBI, he successfully started and managed Cardinal Health’s East Coast biotechnology drug development operations. Prior to Cardinal Health, Dr. Bedu-Addo was an Associate Director at Akzo-Nobel, Senior Scientist at Elan (The Liposome Co.), and Principal Scientist at Schering-Plough. In these positions, he contributed to the development of numerous drugs, including antiviral and anticancer products. Dr. Bedu-Addo obtained his M.S. in Chemical Engineering and Ph.D. in Pharmaceutics from the University of Pittsburgh.#FrankBeduAddo #PDSBiotech #ChemicalEngineering #Pharmaceutics #Liposomes #EnantiospecificCationicLipidNanoparticles #Versamune #IL12 #AntibodyDrugConjugate #HumanPapillomavirus #HPV #HeadAndNeckCancer #UniversalFluVaccines #TumorAssociatedProteins #Oncology #ProgressionFreeSurvival #ProgressPotentialAndPossibilities #IraPastor #Podcast #Podcaster #ViralPodcast #STEM #Innovation #Technology #Science #ResearchSupport the show

Send us Fan MailFiona Cauley ( https://www.fionacauley.com ) is a Nashville-based comedy superstar who uses her comedy for a greater purpose – to raise awareness about her rare, genetic disease, Friedreich's Ataxia (FA), that progressively damages the nervous system, causing loss of muscle control over time, and is found in approximately one in 50,000 people worldwide (5,000 individuals in the United States and 15,000 worldwide).  Diagnosed at just 18 with this degenerative neurological condition, Fiona transformed adversity not just into an amazing career in comedy, but also beyond the stage, as an extremely powerful voice for disability visibility—sharing her story in conversations on podcasts and shows, and using comedy to foster understanding and empathy.Fiona’s style has been defined as both fearless and impactful. She tackles everything from dating while in a wheelchair, to confronting audience discomfort and all sorts of stigma head-on. Dr. David Lynch, MD, PhD, ( https://www.research.chop.edu/people/david-r-lynch ) is an attending neurologist in the Division of Neurology at Children's Hospital of Philadelphia (CHOP) and Director of the Friedreich's Ataxia Program ( https://www.chop.edu/centers-programs/friedreichs-ataxia-program ).Dr. Lynch maintains a dynamic program focused on the Friedreich's Ataxia, which spans clinical, translational, and basic science research efforts on FA that include conducting double-blind clinical trials, identifying biomarkers, and leading mechanistic studies in animal and cellular models of FA.The research conducted by Dr. Lynch and his lab team have led to a greater understanding of the metabolic dysfunction underlying FA. Their work has led to the creation of a patient database as well as a pipeline of more than 20 drug candidates that represent potential new therapies. Dr. Lynch is currently working with pharmaceutical industry partners to develop drug candidates as well as biomarkers for FA.Dr. Lynch has a Medical Degree, and a Ph.D. in Neuroscience, from Johns Hopkins University School of Medicine, Baltimore.Important Episode Links - SKYCLARYS (omaveloxolone) - Patient Site - https://www.skyclarys.com/"Friedreich's Back" - https://adage.com/video/viatris-friedreichs-back-6m38s/#FionaCauley #FriedreichsAtaxia #RareDisease #Comedy #Comedian #DavidLynch #ChildrensHospitalOfPhiladelphia #Neurology #Biogen #Omaveloxolone #CannesLions #Humor #Laughter #Skyclarys #NikkiGlaser #ProgressPotentialAndPossibilities #IraPastor #Podcast #Podcaster #ViralPodcast #STEM #Innovation #Technology #Science #ResearchSupport the show

Send us Fan MailDr. Forrest Ringold, MD of Surgical Association of Mobile ( https://sampadocs.com/about-us/dr-forrest-ringold/ ), is a leading expert in bariatric and robotic surgery and is renowned for his expertise in transforming lives through weight loss surgery and innovative abdominal treatments.With an advanced understanding of both traditional laparoscopic techniques and cutting-edge robotic technology, Dr. Ringold specializes in a wide range of surgical procedures aimed at improving the health and quality of life of his patients, including life-changing weight loss surgeries such as sleeve gastrectomy, gastric bypass, duodenal switch, SADI, and lap band, as well as pioneering advancements in reflux surgery and esophageal and stomach diseases.As a leading authority in his field, Dr. Ringold serves as a key opinion leader for both Intuitive Surgical and Teleflex Medical ( https://www.teleflex.com/usa/en/index.html ), two of the most respected names in medical devices. His innovative approach extends to the latest in gastrointestinal surgery, where he is actively pursuing groundbreaking advancements in magnetic anastomotic technology.Dr. Ringold’s commitment to excellence extends beyond patient care. He is a clinical instructor at the University of South Alabama’s Department of Surgery, where he shares his wealth of knowledge with the next generation of surgeons. His dedication to his craft is also reflected in his leadership roles, including his current position as President of the Alabama State Chapter of the American Society for Metabolic and Bariatric Surgery.Since 2018, Dr. Ringold has led the Epicenter at Mobile Infirmary Medical Center, a distinguished program designed to train surgeons nationwide in the fields of robotic and bariatric surgery.Dr. Ringold attended medical school at University of South Alabama Medical School and did his residency in general surgery at University of South Alabama Medical Center.#ForrestRingold #SurgicalAssociationOfMobile #Bariatric #RoboticSurgery #WeightLossSurgery #SleeveGastrectomy #GastricBypass #DuodenalSwitch #LapBand #MagneticAnastomoticTechnology #TeleflexMedical #SouthAlabamaMedicalSchool #ObesitySurgery #PostoperativeReflux #DeNovoGastroesophagealRefluxDisease #GERD #TitanSGSStapler #SurgicalStaplers #ProgressPotentialAndPossibilities #IraPastor #Podcast #Podcaster #ViralPodcast #STEM #Innovation #Technology #Science #ResearchSupport the show

Send us Fan MailSarah Mastrorocco is Vice President and General Manager of Health at Instacart ( https://www.instacart.com/company/health ), the leading grocery technology company in North America, partnering with more than 1,800 retailers, covering nearly 100,000 stores, and serving over 7,000 consumer packaged goods brands.An innovative leader with extensive expertise in business development and strategy, Sarah spearheaded the creation of Instacart Health and continues to oversee the initiative designed to support consumers, businesses, and nonprofits across three key areas: increasing nutrition security, inspiring healthier choices, and scaling food and nutrition programs within healthcare. In her role, she is focused on expanding consumer health tools and empowering organizations with technology to help improve access to nutritious food and nutrition education. A longtime Instacart veteran, Sarah has played an integral role at the company since joining as the first member of the company’s business development team in 2014. During her tenure, she has held various leadership positions across business development and operations including building relationships with North America’s largest retailers, leading Instacart’s catalog, developing strategic partnerships, and scaling new businesses.Previous to Instacart, Sarah held roles in other CPG companies, including at PepsiCo, in strategy, business innovation, and mergers and acquisitions, as well as at Hershey’s and in the consulting segment.Sarah has an MBA from Northwestern University - Kellogg School of Management and a BS from the McIntire School of Commerce, at University of Virginia.#SarahMastrorocco #Instacart #Health #NutritionSecurity #FoodDesert #SupplementalNutritionAssistanceProgram #MaternalHealth #MaternalOutcomes #FoodAsMedicine #HealthyLabel #Access #SocialDeterminantsOfHealth #HealthOutcomes#ProgressPotentialAndPossibilities #IraPastor #Podcast #Podcaster #ViralPodcast #STEM #Innovation #Technology #Science #ResearchSupport the show